Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
In prior studies, the investigators synthesized 177Lu-EB-PSMA-617 by conjugating a truncated
Evans Blue (EB) molecule and DOTA chelator onto PSMA-617 and labeled it with 177Lu to
increase the tumor accumulation and retention for radioligand therapy，and then the
investigators evaluated the dosimetry of 177Lu-EB-PSMA-617 and response to single low-dose
treatment in patients with metastatic castration-resistant prostate cancer(mCRPC). This study
was performed to evaluate the safety and therapy response to 177Lu-EB-PSMA-617 in patients
with mCRPC.
This is an open-label, randomized study. Different groups with doses of 1.11GBq (30 mCi),
1.85GBq (50 mCi) and 3.7GBq (100 mCi)of 177Lu-EB -PSMA617 will be injected intravenously. All
patients will undergo 68Ga-PSMA PET/CT scans before and after the treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
National Institute for Biomedical Imaging and Bioengineering (NIBIB)